Lakefront Biotherapeutics N.V.
NASDAQ:LKFT · NASDAQ Global Select
-$0.21 today
Vol 0.16M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.9%
avg 9.9%
ROIC
15.4%
avg 15.4%
ROA
9.4%
avg 9.4%
Analysis
ROIC is currently the strongest return metric at 15.4% versus its period average of 15.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Henry Gosebruch | CEO & Executive Director | $1.08M | — | — | — | — |
Annelies Missotten | Executive Officer | — | — | 53 | — | — |
Jeevan Shetty | Head of Clinical Development Oncology | — | — | — | — | — |
John W. Mellors | Head of Cell & Antibody Therapy Discovery | — | — | 88 | — | — |
Fred W. Blakeslee | Executive VP & General Counsel | — | — | — | — | — |
Ellen Van Der Aar | Head of Development | — | — | — | — | — |
Tania Philipp | Chief Human Resources Officer | — | — | 54 | — | — |
Ruiz Astigarraga | Head of Manufacturing Cell Therapy | — | — | — | — | — |
Aaron L. Cox | Chief Financial Officer | — | — | 42 | — | — |
Glenn Schulman D. | Head of Investor Relations | — | — | — | — | — |
Marieke Vermeersch | Head of Corporate Communication | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | -43.7% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | -49.1% (5yr)3 analysts |
Analysis
Forward estimates point to Revenue at -43.7% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages LKFT?
Lakefront Biotherapeutics N.V. (LKFT) lists 11 active executives. The top listed executive is Annelies Missotten, Executive Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.